YU2703A - Bistar vodeni anestetski preparat - Google Patents

Bistar vodeni anestetski preparat

Info

Publication number
YU2703A
YU2703A YU2703A YUP2703A YU2703A YU 2703 A YU2703 A YU 2703A YU 2703 A YU2703 A YU 2703A YU P2703 A YUP2703 A YU P2703A YU 2703 A YU2703 A YU 2703A
Authority
YU
Yugoslavia
Prior art keywords
clear aqueous
propofol
compositions
anesthetic composition
composition
Prior art date
Application number
YU2703A
Other languages
English (en)
Inventor
Srikanth Annappa Pai
Sangeeta Hanurmesh Rivankar
Shilpa Sudhakar Kocharekar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of YU2703A publication Critical patent/YU2703A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Opisani su sterilni farmaceutski stabini autoklavirani bistri preparati propofola (2,6-diizopropil fenol) podesni za parenteralnu primenu. Preparati se uglavnom sastoje od kompleksa propofola sa 2-hidroksipropil-ГЎ-ciklodekstrinom pri masenom odnosu 1:30 do 1:60. Ovaj kompleks propofola sa 2-hidroksipropil-ГЎ-ciklodekstrinom daje bistar vodeni preparat koji je stabilan prema autoklaviranju. Preparat je efikasan kao anestetski agens. Opisan je postupak za dobijanje ovih sinergističkih preparata.[Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-ГЎ-cyclodextrin in a weight ratio of 1:30 - 1:60. This complex of propofol with 2-hydroxypropyl-ГЎ-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.
YU2703A 2000-06-21 2000-12-14 Bistar vodeni anestetski preparat YU2703A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (sh) 2000-06-21 2000-06-21

Publications (1)

Publication Number Publication Date
YU2703A true YU2703A (sh) 2006-03-03

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2703A YU2703A (sh) 2000-06-21 2000-12-14 Bistar vodeni anestetski preparat

Country Status (26)

Country Link
US (1) US7138387B2 (sh)
EP (1) EP1299095B1 (sh)
JP (1) JP4907833B2 (sh)
KR (1) KR100810066B1 (sh)
CN (1) CN1254237C (sh)
AP (1) AP2002002674A0 (sh)
AT (1) ATE267592T1 (sh)
AU (2) AU2001235972B2 (sh)
BG (1) BG107463A (sh)
BR (1) BR0017268A (sh)
CA (1) CA2414064C (sh)
DE (1) DE60011149T2 (sh)
DK (1) DK1299095T3 (sh)
EA (1) EA005589B1 (sh)
ES (1) ES2222271T3 (sh)
HU (1) HUP0301646A3 (sh)
IL (1) IL153387A0 (sh)
IN (1) IN187686B (sh)
MX (1) MXPA02012611A (sh)
NO (1) NO20025999L (sh)
NZ (1) NZ523643A (sh)
PL (1) PL359624A1 (sh)
PT (1) PT1299095E (sh)
WO (1) WO2001097796A1 (sh)
YU (1) YU2703A (sh)
ZA (1) ZA200300336B (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (sh) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
RU2316317C2 (ru) * 2001-12-28 2008-02-10 Эм-Джи-Ай Джи-Пи, Инк. Составленные на основе воды фармацевтические композиции водорастворимых пролекарств пропофола
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CA2494297C (en) * 2002-07-29 2011-10-18 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US20090192230A1 (en) * 2004-01-14 2009-07-30 Koichi Takeda Propofol-containing fat emulsion preparation
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
CA2618799C (en) * 2005-08-12 2013-06-04 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8663874B2 (en) * 2008-03-11 2014-03-04 3M Innovative Properties Company Hardcoat composition
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
JP5583210B2 (ja) 2009-07-21 2014-09-03 スリーエム イノベイティブ プロパティズ カンパニー 硬化性組成物、フォトツールをコーティングする方法、及びコーティングされたフォトツール
US8748060B2 (en) 2009-09-16 2014-06-10 3M Innovative Properties Company Fluorinated coating and phototools made therewith
KR101768237B1 (ko) 2009-09-16 2017-08-14 쓰리엠 이노베이티브 프로퍼티즈 컴파니 플루오르화된 코팅 및 그로 제조된 포토툴
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
AU2012268889B2 (en) 2011-11-29 2013-12-19 Zoetis Services Llc Pharmaceutical compositions
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
WO2017132243A1 (en) * 2016-01-29 2017-08-03 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
NZ523643A (en) 2004-05-28
ES2222271T3 (es) 2005-02-01
CA2414064A1 (en) 2001-12-27
PT1299095E (pt) 2004-10-29
CA2414064C (en) 2013-01-08
NO20025999D0 (no) 2002-12-13
EA005589B1 (ru) 2005-04-28
JP2003535893A (ja) 2003-12-02
IN187686B (sh) 2002-06-08
EP1299095A1 (en) 2003-04-09
DE60011149T2 (de) 2005-07-07
HUP0301646A2 (hu) 2003-09-29
PL359624A1 (en) 2004-08-23
AU3597201A (en) 2002-01-02
CN1254237C (zh) 2006-05-03
CN1454085A (zh) 2003-11-05
ATE267592T1 (de) 2004-06-15
IL153387A0 (en) 2003-07-06
AU2001235972B2 (en) 2005-07-21
EP1299095B1 (en) 2004-05-26
NO20025999L (no) 2002-12-13
BG107463A (en) 2003-11-28
HUP0301646A3 (en) 2005-06-28
WO2001097796A1 (en) 2001-12-27
ZA200300336B (en) 2004-04-08
AP2002002674A0 (en) 2002-12-31
BR0017268A (pt) 2003-05-27
KR100810066B1 (ko) 2008-03-05
KR20030023875A (ko) 2003-03-20
DE60011149D1 (de) 2004-07-01
MXPA02012611A (es) 2004-07-30
US20040014718A1 (en) 2004-01-22
DK1299095T3 (da) 2004-10-11
US7138387B2 (en) 2006-11-21
EA200300047A1 (ru) 2003-06-26
JP4907833B2 (ja) 2012-04-04

Similar Documents

Publication Publication Date Title
YU2703A (sh) Bistar vodeni anestetski preparat
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
SE0001899D0 (sv) New compounds
AR046651A1 (es) Composicion purgante colonica con agente aglutinante soluble
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
PT1390039E (pt) Utilizacao de compostos estrogenicos para aumentar a libido nas mulheres
SI1819227T1 (sl) Farmacevtska formulacija decitabina
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
AU2412695A (en) Taxane class derivative based pharmaceutical compositions
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0409380A (pt) composições farmacêuticas
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide